Project Mitigate

Mitigate for Patients

New: Find out more about minimally invasive treatment options developed in MITIGATE!

The outcomes of the MITIGATE project will have a major, positive impact on the health of GIST patients and improve the available standard of care. This project is very unusual because scientists and doctors from many fields are working together to improve the way GIST patients are treated.

A better, faster way of taking biopsies using robotics will also be developed. This will reduce the pain and discomfort for patients, allow for faster recovery, and will speed up the decision-making about the best treatment for each patient. The biopsy sample will give information about the best drug to use for the patient, as well as confirming the diagnosis. This will reduce the stress for the patient.

Computer models will be used to find the best radio-active drugs to be used in the scans used to monitor tumours and then in actual treatment of the tumours.  In the end, this will reduce the amount of radiation given to the patient, lowering the risk of secondary cancers caused by the radiation. This use of radio-active molecules either absorbed by, or actually placed in the tumours is a new treatment for GIST.

The project is also developing new and more accurate ways of killing tumours using heat, or molecular-imaging guided percutaneous thermal ablation. This uses 3D imaging to increase the accuracy of the treatment. The tumour can then be “attacked” from different directions.

The multidisciplinary approaches MITIGATE is developing will be more efficient and its indication will be better standardised. With these new treatments, the care of GIST patients with metastatic disease, who are no longer responding to the tyrosine kinase inhibitors imatinib and sunitinib, will be greatly improved. The treatment will be an example of personalised treatment.

In consequence, this will improve patient outcome by making local treatment for metastatic disease more efficient and standardised. Patients will benefit from the proof-of-concept studies characterising TKI-resistant GIST, as this will form the basis for advancing personalised treatment beyond drugs.